Screade® | FDA Approves First Gene Therapy for Treatment of Aromatic

PetsBusiness

FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency - FDA.gov

FDA Approves Kebilidi, the first gene therapy indicated for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency.